STOCK TITAN
  1. Home
  2. News
  3. AZN

AstraZeneca PLC - AZN STOCK NEWS

Welcome to our dedicated page for AstraZeneca PLC news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.

AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.

The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.

Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.

Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.

With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.

News

WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

Rhea-AI Summary
AstraZeneca and Ionis' WAINUA™ (eplontersen) has been approved by the US FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The approval is based on the NEURO-TTRansform Phase III trial, showing consistent and sustained benefit in improving neuropathy impairment and quality of life. WAINUA is the only approved medicine for ATTRv-PN that can be self-administered via an auto-injector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
News

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) to receive $10 million milestone payment from AstraZeneca for dosing the first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
clinical trial
-
News

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes

Rhea-AI Summary
Daiichi Sankyo (4568) and AstraZeneca (AZN) initiate two global, randomized phase 3 trials for neoadjuvant and advanced triple negative breast cancer treatments with datopotamab deruxtecan and durvalumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
clinical trial
News

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Rhea-AI Summary
AstraZeneca (NASDAQ: ICVX) has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will strengthen AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12, targeting both RSV and hMPV, two leading causes of severe respiratory infection and hospitalization in adults 60 years of age and older and those with chronic conditions. The upfront cash portion of the consideration represents a transaction value of approximately $0.8bn, a 43% premium to Icosavax’s closing market price on 11th December 2023. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $1.1bn, a 91% premium to Icosavax’s closing market price on 11th December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
acquisition clinical trial
-
News

Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis

Rhea-AI Summary
Alexion Pharmaceuticals, Inc. (ALXN) announced positive results from the ALPHA Phase III trial showing that danicopan, as an add-on to ULTOMIRIS or SOLIRIS, demonstrated sustained clinical benefit for patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH). Hemoglobin levels improved with danicopan at 12 weeks and were maintained through 48 weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
clinical trial
-
News

Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer

Rhea-AI Summary
GRAIL, LLC (AZN) presented validation results for a plasma-based targeted methylation assay for early-stage lung cancer at the North America Conference on Lung Cancer 2023. The assay demonstrated the potential to identify high-risk patients who might benefit from additional treatment. The clinical validation studies showed that the presence of ctDNA correlated with an inferior two-year recurrence-free survival, and ctDNA positivity was associated with higher rates of mediastinal nodal upstaging at resection, PD-L1 positivity, and grade 3 histology. Analytical studies also demonstrated high analytical specificity, accuracy to detect signal at low ctDNA input, and a robust LoD95 of tumor methylated fraction. GRAIL has a strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic assays for use with AstraZeneca’s therapies, and the company has announced the availability of its state-of-the-art research use only methylation solution for custom oncology applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology

Rhea-AI Summary
Presage Biosciences (AZN) partners with AstraZeneca to utilize CIVO platform for translational analysis in head and neck cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
partnership
-
News

AstraZeneca advances scientific leadership in hematology at ASH 2023

Rhea-AI Summary
AstraZeneca to present new clinical and real-world data at the 65th ASH Annual Meeting and Exposition, showcasing long-term benefits of CALQUENCE in chronic lymphocytic leukemia and potential of danicopan in paroxysmal nocturnal hemoglobinuria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
News

Major Milestone Met in AI-Powered Fight Against Lung Cancer

Rhea-AI Summary
AstraZeneca (AZN) joins the WEF EDISON Alliance to improve global lung health with a 5-million lung health AI commitment. The initiative leverages AI to screen for lung cancer risk in routine X-rays, identifying high-risk nodules in resource-constrained regions. The partnership with Qure.ai aims to eliminate lung cancer as a global cause of death, with a focus on digital inclusion and improving patient outcomes. AstraZeneca's A.Catalyst Network and the Lung Ambition Alliance are integral components of this proactive initiative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
AI
News

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes

Rhea-AI Summary
AstraZeneca: Launches Evinova, a leading provider of digital health solutions for healthcare professionals, regulators, and patients. Evinova collaborates with Parexel, Fortrea, Accenture, and Amazon Web Services to offer digital products globally. Evinova's suite includes unified trial solution, study design and planning, and portfolio management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
clinical trial

FAQ

What is the current stock price of AstraZeneca PLC (AZN)?

The current stock price of AstraZeneca PLC (AZN) is $67.01 as of January 10, 2025.

What is the market cap of AstraZeneca PLC (AZN)?

The market cap of AstraZeneca PLC (AZN) is approximately 207.8B.

What is AstraZeneca PLC?

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It is headquartered in Cambridge, England.

What therapeutic areas does AstraZeneca focus on?

AstraZeneca’s product portfolio includes drugs across several therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Where does AstraZeneca generate most of its revenue?

A significant portion of AstraZeneca’s revenue comes from international markets, with the United States accounting for nearly one-third of its sales.

What is the recent collaboration between AstraZeneca and Nona Biosciences about?

AstraZeneca and Nona Biosciences have entered into a global license agreement to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology.

What is C-CAR031?

C-CAR031 is a GPC3-targeted CAR-T therapy developed by AstraZeneca and AbelZeta Pharma for treating hepatocellular carcinoma (HCC). Initial clinical results have shown promising safety and efficacy data.

What is rilvegostomig?

Rilvegostomig is a PD-1/TIGIT bispecific antibody developed by AstraZeneca in collaboration with Compugen Ltd. It is currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer.

What are some of AstraZeneca’s key recent achievements?

Recent achievements include a global license agreement with Nona Biosciences for oncology therapies, collaboration with AbelZeta Pharma on C-CAR031, and partnership with Compugen Ltd. for developing rilvegostomig.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered at the Cambridge Biomedical Campus in Cambridge, England.

When was AstraZeneca formed?

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK.

What is the focus of AstraZeneca’s research and development?

AstraZeneca focuses on research and development in pharmaceuticals and biotechnology, particularly in creating treatments for various major therapeutic areas including cancer, respiratory diseases, cardiovascular conditions, and more.
Stock AZN logo
AstraZeneca PLC

Nasdaq:AZN

AZN Rankings

#40 Ranked by Market Cap
#1616 Ranked by Dividends

AZN Stock Data

207.80B
3.10B
0.01%
16.77%
0.32%
Drug Manufacturers - General
Healthcare
Link
United States of America
Cambridge